ThromboGenics ophthalmic news

ThromboGenics said it will remain independent after a review of strategic options, including a potential sale. In February, the company hired Morgan Stanley to explore strategic options as a result of a struggle to gain uptake in the U.S. of its sole marketed product, Jetrea ocriplasmin. The drug is approved in the U.S. to treat symptomatic vitreomacular adhesion (VMA) and in the EU to treat vitreomacular traction (VMT) (see BioCentury, March 3). ...